Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment : Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation

MLA

Saito, Yoshitaka, et al. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment : Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1400957672&authtype=sso&custid=ns315887.

APA

Saito, Y., Takekuma, Y., Komatsu, Y., & Sugawara, M. (2021). Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment : Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.

Chicago

Saito, Yoshitaka, Yoh Takekuma, Yoshito Komatsu, and Mitsuru Sugawara. 2021. “Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment : Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1400957672&authtype=sso&custid=ns315887.